[ad_1]
Aeras, a non-profit organization, announced the release of comprehensive results from a randomized, controlled phase 2 clinical trial of 2 TB vaccines.
This proof-of-concept study showed that vaccination can reduce In this study, BCG revaccination significantly reduced tuberculosis infections in adolescents with a vaccine efficacy of 45.4%.
In addition, the experimental vaccine, H4: IC31, However, the trend observed for H4: IC31 is the first time that a subunit vaccine has shown a signal that it might be able to protect against tuberculous infection.
Jacqueline Shea, Ph.D., CEO of Aeras, said, "With this study we have shown that vaccines against tuberculosis infection can work."
"The Results"
"BCG results are important results that have important implications for public health and could save millions of lives," he said, Dr. Shea says. [19659002TuberculosiscausesmoredeathsthananyotherinfectiousagentandisincreasinglycharacterizedbyantimicrobialresistanceaccordingtoWHO104millionnewTBcaseswerereportedin2016and17milliondeaths
BCG is the only globally licensed tuberculosis vaccine.
H4: IC31 is a subunit candidate vaccine jointly developed by Aeras and Sanofi Pasteur, and the Statens Serum Institute
L & # The clinical trial was funded by Sanofi Pasteur, the UK Department for International Development, the Bill & Melinda Gates Foundation, and Aeras
.The Tuberculosis Vaccination Initiative (SATVI) at the University of Cape Town and Centr Research Emavundleni (part of the Desmond Tutu HIV Center). The study was approved by the Medicines Control Council of South Africa and the local independent competent ethics committees.
Source link
